Full name

Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)

NCT Number
NCT04167358
Geography
US
Non-US
Locations

Argentina, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Mexico, Poland, Russian Federation, Spain, United Kingdom, United States

Primary Endpoints
  • Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs). Up to 66 months
  • Number of participants with Severe AEs. Up to 66 months
Order
0
Disease
PBC
Menu title
Linerixibat Long-term Safety, and Tolerability Study (LLSAT)
Version
NMA 2025
Phase
3
Status
Active, not recruiting